Travere Therapeutics (NASDAQ: TVTX)
Travere Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Travere Therapeutics Company Info
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.
News & Analysis
Why Shares of Travere Therapeutics Are Slumping Thursday
A mixed trial could hurt a kidney drug's chances of full approval.
Could an FDA Approval Send This Stock Flying?
Is now the time to load up on this struggling stock?
Why Travere Therapeutics Stock Bolted Higher This Week
A high-value regulatory approval lit a fire underneath the biotech's shares this week.
Here's Why Travere Therapeutics Stock Is Climbing Today
Investors are cheering positive phase 3 trial results with sparsentan that suggest it could become an important new treatment for a rare kidney disease.
Why Travere Therapeutics Stock Is Plummeting Today
The FDA quashes the company's hopes for accelerated approval of a key pipeline drug.
3 Companies to Watch At Kidney Week 2019
Keeping up with the news from major medical meetings has become a requirement for healthcare investors.
Why Tilray, Splunk, and Retrophin Slumped Today
Find out how earnings and other factors hit these stocks.
Why Retrophin, Inc. Is Tanking Today
Retrophin's PKAN drug candidate missed the mark in a late-stage trial.
Valuation
Earnings Transcripts
Retrophin (RTRX) Q1 2020 Earnings Call Transcript
RTRX earnings call for the period ending March 31, 2020.
Retrophin (RTRX) Q4 2019 Earnings Call Transcript
RTRX earnings call for the period ending December 31, 2019.
Retrophin (RTRX) Q3 2019 Earnings Call Transcript
RTRX earnings call for the period ending September 30, 2019.
Retrophin (RTRX) Q2 2019 Earnings Call Transcript
RTRX earnings call for the period ending June 30, 2019.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.